Urodynamic Systems in Minnesota

Coloplast A/S is a Denmark-based multinational manufacturer of intimate healthcare solutions serving 2 million+ patients across 100+ countries. The company specializes in six primary care areas: Ostomy Care (pouching systems and related products for colostomy, ileostomy, and urostomy patients); Continence Care (intermittent catheters and urinary collection devices); Interventional Urology (implants, surgical slings, and urology instruments); Bowel Care (transanal irrigation systems for bowel management); Wound & Tissue Repair (advanced wound dressings and biologic products); and Voice and Respiratory Care (voice prostheses, heat and moisture exchangers, tracheostomy tubes, and adhesives). Coloplast manufactures and distributes medical devices and consumables directly and through distributors in markets where subsidiaries are not established. The company operates customer care centers globally and provides comprehensive support services through Coloplast Care (patient support and education) and Coloplast Professional (healthcare provider training and clinical resources). Products are designed with user-centered innovation informed by patient feedback. The company maintains regulatory compliance across major markets and serves hospitals, clinics, home care settings, and individual patients. Coloplast is publicly listed on the Copenhagen Stock Exchange (ticker: COLO B).

GOTOP Medical, Inc. manufactures the RigiScan® Plus, an ambulatory diagnostic system for erectile dysfunction assessment. The RigiScan® Plus is a non-invasive, cost-effective diagnostic tool designed to measure the frequency, rigidity, and duration of both nocturnal and provocative erections in a clinical or home ambulatory setting. The device provides physicians with objective graphical and tabular data on penile base and tip rigidity and tumescence, enabling differentiation between organic and psychological erectile dysfunction. Testing can be conducted in stand-alone mode or real-time monitoring mode when connected to a computer. The system is used by urology and sexual medicine specialists for diagnostic evaluation and treatment planning. The company holds the registered trademark for RigiScan® and markets this device internationally, including in European Union markets where regulatory approval has been obtained.

Biobot Surgical is a Singapore-based manufacturer of robotic-assisted surgical systems for transperineal prostate procedures and soft tissue ablation. The company's flagship product, the Mona Lisa platform, delivers submillimeter robotic accuracy (±1.0 mm) for precision needle positioning in prostate biopsy and treatment applications. The Mona Lisa [DX] system, launched in 2017, enables MRI-ultrasound image fusion for targeted prostate biopsies with higher detection rates than traditional transrectal approaches and minimal infection risk. The newer Mona Lisa 2.0 [TX] expands indications to include percutaneous soft tissue ablation therapy. The company reports over 50 systems installed globally and more than 23,000 completed procedures as of January 2024. Regulatory credentials include FDA clearance for both DX and TX models, CE certification (TX model), TGA approval (Australia), NMPA clearance (China), and HSA approval (Singapore). Biobot operates a development pipeline including the Mona Lisa ACCuESS platform to expand sites of care and clinical indications. The company maintains a USA office in Saint Paul, Minnesota, headquarters in Singapore, and an Asia-Pacific regional office in Shanghai. Target market includes hospital urology departments and ambulatory surgery centers performing prostate cancer diagnostics and therapeutic interventions.